Latest Content

Diagnosed with bone cancer at 14, college setter Gabby Orlet shares how volleyball, honesty and her family carried her through years of treatment.

In the phase 3 RT CHARM trial, published Oct. 12, 2026, in the Journal of Clinical Oncology, a three-week course of radiation after mastectomy caused about the same rate of reconstruction complications as the standard five-week course in women with breast cancer.

Since September 2024, every U.S. mammogram report must tell patients whether their breast tissue is dense. Here is what that notice means, why it matters and what to ask your care team.

Noah Elliott, now a Paralympic snowboarder, counted small wins during inpatient chemotherapy and found inspiration in the youngest children on his hospital floor.

Diagnosed with stage 4 breast cancer weeks after giving birth, Eileen Carter and her chaplain husband share why a second opinion changed everything.

Five colorectal cancer trials recently began treating patients, testing targeted drugs, bispecific antibodies and immunotherapy. Here’s what each one is studying.

The FDA flagged potential safety signals for colitis with Ibrance, Kisqali and Verzenio, and heart inflammation with melanoma drugs. No causal link is confirmed.

A biomarker test changed one mother’s diagnosis from suspected glioblastoma to ependymoma, but the report written in October did not reach her until December.

Anktiva is now approved for BCG-unresponsive papillary-only bladder cancer. Here’s what the bladder-sparing option involves, from timeline to risks.

The 2026 cancer report found U.S. cancer death rates continued to fall from 2019 to 2023, largely due to lung cancer progress, while diagnoses rose slightly among women.

Patients with a newly identified tumor state had shorter survival following chemotherapy and immunotherapy, potentially helping doctors identify those at greater risk of poor outcomes.

Longer follow-up of the phase 2 LUNAR trial showed a 62% lower risk of progression, additional hormone therapy or death with 177Lu-PNT2002 plus radiation.

Medicare's cap on out-of-pocket drug costs has made cancer pills more affordable, but premiums, formularies and prior authorization rules still vary widely. Here's a checklist.